Our top pick for
Alkermes plc is a biotechnology business based in the US. Alkermes shares (ALKS) are listed on the NASDAQ and all prices are listed in US Dollars. Alkermes employs 2,245 staff and has a trailing 12-month revenue of around 0.00.
|52-week range||$13.12 - $23.92|
|50-day moving average||$19.82|
|200-day moving average||$19.59|
|Wall St. target price||$22.11|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-1.17|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing Alkermes stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Alkermes's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Alkermes's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $3.8 million.
The EBITDA is a measure of a Alkermes's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$1 billion|
|Gross profit TTM||$860.4 million|
|Return on assets TTM||-3.74%|
|Return on equity TTM||-10.3%|
|Market capitalisation||$3.5 billion|
TTM: trailing 12 months
There are currently 12.2 million Alkermes shares held short by investors – that's known as Alkermes's "short interest". This figure is 1.3% down from 12.4 million last month.
There are a few different ways that this level of interest in shorting Alkermes shares can be evaluated.
Alkermes's "short interest ratio" (SIR) is the quantity of Alkermes shares currently shorted divided by the average quantity of Alkermes shares traded daily (recently around 1.1 million). Alkermes's SIR currently stands at 11.61. In other words for every 100,000 Alkermes shares traded daily on the market, roughly 11610 shares are currently held short.
However Alkermes's short interest can also be evaluated against the total number of Alkermes shares, or, against the total number of tradable Alkermes shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Alkermes's short interest could be expressed as 0.08% of the outstanding shares (for every 100,000 Alkermes shares in existence, roughly 80 shares are currently held short) or 0.1091% of the tradable shares (for every 100,000 tradable Alkermes shares, roughly 109 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Alkermes.
Find out more about how you can short Alkermes stock.
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Alkermes.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Total ESG risk: 28.83
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Alkermes's overall score of 28.83 (as at 12/31/2018) is nothing to write home about – landing it in it in the 53rd percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Alkermes is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Environmental score: 0.37/100
Alkermes's environmental score of 0.37 puts it squarely in the 1st percentile of companies rated in the same sector. This could suggest that Alkermes is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Social score: 17.49/100
Alkermes's social score of 17.49 puts it squarely in the 1st percentile of companies rated in the same sector. This could suggest that Alkermes is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Governance score: 8.71/100
Alkermes's governance score puts it squarely in the 1st percentile of companies rated in the same sector. That could suggest that Alkermes is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Controversy score: 1/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. Alkermes scored a 1 out of 5 for controversy – the highest score possible, reflecting that Alkermes has managed to keep its nose clean.
|Total ESG score||28.83|
|Total ESG percentile||53.12|
|Environmental score percentile||1|
|Social score percentile||1|
|Governance score percentile||1|
|Level of controversy||1|
We're not expecting Alkermes to pay a dividend over the next 12 months.
Alkermes's shares were split on a 2:1 basis on 14 May 2000. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Alkermes shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Alkermes shares which in turn could have impacted Alkermes's share price.
Over the last 12 months, Alkermes's shares have ranged in value from as little as $13.12 up to $23.92. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Alkermes's is 0.9151. This would suggest that Alkermes's shares are less volatile than average (for this exchange).
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA (aripiprazole lauroxil), an extended-release intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL (naltrexone for extended-release injectable suspension) for the treatment of alcohol and opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA to treat schizophrenia; and VUMERITY (diroximel fumarate) for the treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting and active secondary progressive diseases. The company is also developing LYBALVI (olanzapine/samidorphan), an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and nemvaleukin alfa, an engineered fusion protein to expand tumor-killing immune cells and to avoid the activation of immunosuppressive cells. It has collaboration agreements with Janssen Pharmaceutica N. V. , Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International; a license agreement with Acorda Therapeutics, Inc. ; and a license and collaboration agreement with Biogen Swiss Manufacturing GmbH.
Everything we know about the Krispy Kreme IPO, plus information on how to buy in.
Everything we know about the Day One Biopharmaceuticals IPO, plus information on how to buy in.
Everything we know about the Enact Holdings IPO, plus information on how to buy in.
Everything we know about the Solid Power IPO, plus information on how to buy in.
Everything we know about the Paymentus Holdings IPO, plus information on how to buy in.
Everything we know about the Qiniu Limited IPO, plus information on how to buy in.
Everything we know about the Qiniu Limited IPO, plus information on how to buy in.
Everything we know about the Ximalaya IPO, plus information on how to buy in.
Everything we know about the Zeta Global Holdings Corp IPO, plus information on how to buy in.
Everything we know about the Paycor HCM IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.